Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, the Department of Radiology and Imaging Sciences, and the Department of Pathology, University of Utah Health, Intermountain Healthcare, and Primary Children's Hospital, Salt Lake City, Utah.
Corresponding author: Brett D. Einerson, MD, MPH, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, UT; email: [email protected].
Brett D. Einerson was supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development (K23HD106009) during the completion of this work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Financial Disclosure Anne Kennedy disclosed receiving payment from: Elsevier Royalties; World Class CME for speaker honorarium and hotel costs; SMFM for speaker honorarium; and UC Davis for lecture honorarium. D. Ware Branch disclosed the following: Member, UCB Women with Inflammatory Disease Advisory Board. Meeting, September 12, 2020. Swanson, Martin & Bell: medical expert consultancy, check issued September 21, 2020. Obstetric antiphospholipid syndrome: Diagnosis, treatment, controversies. American Society for Clinical Laboratory Service Region VIII Annual Seminar, October 20, 2020. Association of Idaho Rheumatologists. Obstetric antiphospholipid syndrome. December 4, 2021. Bendin Sumrall & Ladner: medical expert consultancy. Michigan Professional Insurance Exchange medical expert consultancy. Gershon, Willoughby & Getz: medical expert consultancy. Snow, Christensen & Matineau: medical expert consultancy. Grand Rounds, University of New York, Stonybrook, November 3, 2021. TNF-alpha Blockade with Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS Annual Direct Costs: $143,980 NIH/NIAMS R21AR21069189-03S1 Role: Co-Principal Investigator (with Dr. JE Salmon, MD) 05/11/16-Present: Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE Direct Costs: $190,124, Total Costs: $252,295. UCB Pharma Inc. Role: Principal Investigator. Jessica Comstock disclosed receiving payment from Amirsys. Paula J. Woodward disclosed receiving book royalties from Elsevier (not relevant to this work). The other authors did not report any potential conflicts of interest.
The authors thank the ultrasonographers at the Utah Placenta Accreta Program, whose skills were critical in evaluating patients with placenta accreta spectrum, and the research staff in the Department of Obstetrics and Gynecology and the Obstetrics and Gynecology Research Network at the University of Utah for enrolling placenta accreta spectrum patients in this study, performing intraoperative photography, and transporting specimens between departments and hospitals.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/D24.
